©2017 Biogen. All Rights Reserved.
TYSABRI® (natalizumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) to slow the worsening of symptoms common in people with MS and to decrease the number of flare-ups (relapses). TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML). When starting and continuing treatment with TYSABRI, it is important to discuss with your doctor whether the expected benefit of TYSABRI is enough to outweigh this risk.
TYSABRI increases your risk of getting a rare brain infection—called progressive multifocal leukoencephalopathy (PML)—that usually leads to death or severe disability.
Before receiving TYSABRI, it is important to tell your doctor:
TYSABRI can cause serious side effects. If you have any of the symptoms listed below, call your doctor right away:
The most common side effects of TYSABRI are:
These are not all of the possible side effects of TYSABRI. For more information, ask your doctor. To report side effects to FDA, please call 1-800-FDA-1088.Please see Full Prescribing Information including Boxed Warning and Medication Guide. This information is not intended to replace discussions with your healthcare provider.
PLEGRIDY® (peginterferon beta-1a) is a prescription medicine used to treat people with relapsing forms of multiple sclerosis (MS).
Before beginning treatment, you should discuss with your healthcare provider the potential benefits and risks associated with PLEGRIDY.
PLEGRIDY can cause serious side effects. Call your healthcare provider right away if you have any of the symptoms listed below.
Do not take PLEGRIDY if you are allergic to interferon beta or peginterferon beta-1a, or any of the other ingredients in PLEGRIDY.
Before taking PLEGRIDY, tell your healthcare provider if you:
PLEGRIDY can cause additional serious side effects including:
The most common side effects of PLEGRIDY include:
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
ZINBRYTA (daclizumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS). Because of its risks, ZINBRYTA is generally used in people who have tried 2 or more MS medicines that have not worked well enough. It is not known if ZINBRYTA is safe and effective for use in children under 18 years of age.
ZINBRYTA can cause serious side effects, including:
Liver problems, including autoimmune-related liver problems that may lead to death. Your healthcare provider will do blood tests to check your liver before starting ZINBRYTA, every month while you are using ZINBRYTA, and monthly for 6 months after you stop using ZINBRYTA.
Call your healthcare provider right away if you have any of the following symptoms of liver problems: nausea or vomiting, stomach pain, unusual tiredness, not wanting to eat, yellowing of the skin or whites of your eyes, or dark urine.
Immune system problems. Some people using ZINBRYTA develop immune-mediated disorders, where the body's immune system attacks healthy cells in the body, and other immune system problems.
Call your healthcare provider right away if you have any of the following symptoms: skin reactions, such as rash or skin irritation; tender, painful, or swollen lymph nodes; symptoms of a low red blood cell count, which can include looking very pale, feeling more tired than usual, dark urine, shortness of breath, or yellowing of the skin or whites of your eyes; intestinal problems (colitis), symptoms of which can include fever, stomach pain, blood in your stools, or diarrhea that does not go away; or any new and unexplained symptoms in any part of your body.
Because of the risk of serious liver problems and immune system problems, ZINBRYTA is only available through a restricted program called the ZINBRYTA Risk Evaluation and Mitigation Strategy (REMS) Program.
Do not use ZINBRYTA if you: have liver problems; have or have had autoimmune-related liver problems including autoimmune hepatitis; or are allergic to daclizumab or any of the other ingredients in ZINBRYTA.
Before using ZINBRYTA, tell your healthcare provider if you have or have had: liver problems; skin problems, including eczema or psoriasis; tuberculosis or an active infection; are planning to receive a vaccine; have or have had depression; are pregnant or planning to become pregnant; are breastfeeding or planning to breastfeed. It is not known if ZINBRYTA will harm your unborn baby or if ZINBRYTA passes into your breast milk.
Tell your health care provider about all the medicines, vitamins or supplements you take. Using ZINBRYTA with certain medicines can cause serious side effects.ZINBRYTA can cause other serious side effects, including:
The most common side effects of ZINBRYTA include: upper respiratory tract infection; flu, pain or swelling in your nose, throat, or mouth; bronchitis; abnormal liver function tests; dry, itchy, scaly, or inflamed skin (eczema); rash; depression and depressed mood; and swollen lymph glands. Tell your healthcare provider if you have any side effect that bothers you or does not go away.These are not all the possible side effects of ZINBRYTA. To report side effects to FDA, please call 1-800-FDA-1088.
If you cannot afford your medication, Biogen and AbbVie may be able to help. Contact 1-800-456-2255 for more information.
©2017 Biogen. All rights reserved.